Exclusive Online Content
Kindeva Drug Delivery, Chiesi Group & H&T Presspart Announce Strategic Partnership for Dose Counter Technology Production
Kindeva Drug Delivery and H&T Presspart are partnering with Chiesi Group for the installation of a production line for dose counter (DC) and dose indicator (DI) devices. Combining the specific….
Acquisition of Solus BioTech Expands Croda's Specialized Pharma Business in Asia
Croda International Plc recently announced it has acquired Solus BioTech, a global leader in premium, biotechnology-derived materials, from Solus Advanced Materials…..
LIfT BioSciences Heralds a New Era of Affordable Effective Cancer Cell Therapies Simply Produced From iPSCs
LIfT BioSciences recently announced successful proof-of-concept production of its patented cancer killing alpha neutrophils from induced….
Caribou Biosciences Announces $25-Million Equity Investment From Pfizer
Caribou Biosciences, Inc. recently announced Pfizer Inc. has made a $25-million equity investment in the company. Pfizer purchased 4,690,431 of Caribou common shares at a price of….
Adare Pharma Solutions Announces Divestiture of Postbiotics Pioneer Adare Biome to dsm-firmenich
Adare Pharma Solutions recently announced the completion of its divestiture of its Adare Biome business unit, a pioneer in the development and manufacturing of postbiotics, to dsm-firmenich, innovators in….
F-star Announces Strategic Collaboration & License Agreement With Takeda
F-star Therapeutics, an invoX company, recently announced it has entered into a strategic discovery collaboration and licensce agreement with….
Enterome Announces First Patient Dosed in Phase 1/2 Trial With Third OncoMimics Immunotherapy in Metastatic Colorectal Cancer
Enterome recently announced the first patient was dosed in the Phase 1/2 AUDREY trial evaluating EO4010, the company’s third OncoMimics candidate, for the treatment of patients with….
Ascendia Pharmaceuticals Develops Novel Nanoemulsion IV Formulation for Clopidogrel That Received IND Approval
Ascendia Pharmaceuticals CEO Jim Huang, PhD, recently announced Ascendia’s patented Emulsol® nanotechnology has been used to develop a novel nanoemulsion IV formulation for….
MoonLake Immunotherapeutics Achieves Landmark Milestone With Positive Phase 2 Results for Nanobody Sonelokimab in Hidradenitis Suppurativa
MoonLake Immunotherapeutics recently announced positive top-line results from its global Phase 2 MIRA trial evaluating the efficacy and safety of the Nanobody sonelokimab in patients with moderate-to-severe….
Ocean Biomedical Announces US Patent Issued for Bispecific Cancer Immunotherapy Treatment With Demonstrated Killing of Tumor Cells in Lung Cancer, Brain Cancer (Glioblastoma) & Metastatic Melanoma
Patent broadens protection around Ocean Biomedical’s first-in-class anti-CHi3L1 antibody to include new bispecific approaches targeting immune checkpoints, with potential application in….
EXCLUSIVE ONLINE CONTENT
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing With Personalized Cancer Vaccine
Significant Phase 2 clinical trial progress obtained with first patient finalizing EVX-01 vaccine dosing….
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration With Neurocrine Biosciences, Triggering Milestone Payment
Voyager Therapeutics, Inc. recently announced the joint steering committee with its collaborator Neurocrine Biosciences has selected a lead development candidate in the GBA1 gene therapy program for the potential treatment of Parkinson’s disease….
Kincell Bio & Imugene Announce Strategic Manufacturing & Process Development Partnership
Kincell Bio to acquire Imugene’s North Carolina manufacturing facility for up to $6M USD in upfront and milestone-driven payments over 3 years….
Cullinan Therapeutics Announces Strategic Expansion Into Autoimmune Diseases & $280-Million Private Placement
CLN-978 clinical development to focus exclusively on autoimmune diseases, pursuing systemic lupus erythematosus as a first indication….
BC Platforms & NTT Group Announce Official Opening Ceremony for Exclusive Collaboration & Launch of Japanese Precision Medicine Platform
BC Platforms (BCP) recently announces an exclusive collaboration with NTT Life Science Corporation, a company in the medical field of the NTT Group, to accelerate data-driven….